aid: immune-onc-therapeutics
name: Immune-Onc Therapeutics
description: >-
  Immune-Onc Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Palo
  Alto, California, founded in 2016 by Charlene Liao and Guo Liang Yu. The company develops novel
  antibody therapeutics that target myeloid cell inhibitory receptors — with a current focus on the
  Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) — to treat blood cancers, solid tumors,
  and autoimmune and inflammatory disease. Its clinical pipeline includes IO-108, a fully human IgG4
  antagonist antibody targeting LILRB2 (ILT4) in Phase 1b/2 for solid tumors including hepatocellular
  carcinoma, and IO-202, a first-in-class IgG1 antibody targeting LILRB4 (ILT3) in Phase 1b for acute
  myeloid leukemia and chronic myelomonocytic leukemia, which holds FDA Fast Track and Orphan Drug
  designations. Preclinical programs include IO-312, a LILRB4-directed bispecific antibody, and IO-106
  targeting LAIR1. The company has clinical collaborations with BeiGene, Regeneron, and Roche, and has
  raised approximately $138 million across Series A and Series B financings from investors including
  Northern Light Venture Capital, Vivo Capital, CLI Ventures, and the Stanford-StartX Fund. Immune-Onc
  is a therapeutics developer, not a software or platform company: as of this profile it publishes no
  public API, developer portal, OpenAPI or other machine-readable contract, no SDKs, no public GitHub
  organization and no /.well-known/ discovery surface — its only machine-readable documents are two
  Squarespace RSS feeds for its news and press-release collections. This record therefore captures the
  company's verified public identity, its published web properties, its clinical-trial registry
  presence, and the probed security posture of its public web surface.
url: https://raw.githubusercontent.com/api-evangelist/immune-onc-therapeutics/refs/heads/main/apis.yml
image: https://static1.squarespace.com/static/60dc8b9325bba74a54bb572f/t/61003c309aa7560407b4842f/1627405360143/Imune-Onc%2BTheraputics_Logo%2BIteration_Final4-03.png?format=1500w
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-08-04'
  method: derived
specificationVersion: '0.23'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- Oncology
- Immunotherapy
- Immuno-Oncology
- Antibodies
- Clinical Trials
- Life Sciences
- Healthcare
- Drug Development
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/immune-onc-therapeutics-domain-security.yml
- type: WellKnown
  url: well-known/immune-onc-therapeutics-well-known.yml
- type: LLMsTxt
  url: llms/immune-onc-therapeutics-llms.txt
- type: Website
  url: https://www.immune-onc.com/
- type: Team
  url: https://www.immune-onc.com/team
- type: Pipeline
  url: https://www.immune-onc.com/pipeline
- type: Publications
  url: https://www.immune-onc.com/publications-abstracts
- type: PressReleases
  url: https://www.immune-onc.com/press-releases
- type: News
  url: https://www.immune-onc.com/news
- type: Blog
  url: https://www.immune-onc.com/news-1
- type: BlogRSS
  url: https://www.immune-onc.com/news-1?format=rss
- type: BlogRSS
  url: https://www.immune-onc.com/pr-posts?format=rss
- type: Careers
  url: https://www.immune-onc.com/careers
- type: ForPatients
  url: https://www.immune-onc.com/for-patients
- type: ExpandedAccessPolicy
  url: https://www.immune-onc.com/expanded-access-policy
- type: ClinicalTrials
  url: https://clinicaltrials.gov/search?spons=Immune-Onc%20Therapeutics
- type: LinkedIn
  url: https://www.linkedin.com/company/immune-onc-therapeutics
- type: SecondaryMarket
  url: https://forgeglobal.com/immune-onc-therapeutics_stock/
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 1
  pass: local-v1